CN103242273B - 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 - Google Patents
2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 Download PDFInfo
- Publication number
- CN103242273B CN103242273B CN201210028895.0A CN201210028895A CN103242273B CN 103242273 B CN103242273 B CN 103242273B CN 201210028895 A CN201210028895 A CN 201210028895A CN 103242273 B CN103242273 B CN 103242273B
- Authority
- CN
- China
- Prior art keywords
- compound
- methyl
- preparation
- esi
- pharmacologically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BGMHQBQFJYJLBP-UHFFFAOYSA-N C#Cc1ccc(C=O)cc1 Chemical compound C#Cc1ccc(C=O)cc1 BGMHQBQFJYJLBP-UHFFFAOYSA-N 0.000 description 1
- MTGHDMSHFPXRNT-UHFFFAOYSA-N C#Cc1ccc(C=O)cn1 Chemical compound C#Cc1ccc(C=O)cn1 MTGHDMSHFPXRNT-UHFFFAOYSA-N 0.000 description 1
- OLOHEKLZHBXCOU-UHFFFAOYSA-N CN1CCN(Cc(cc2)ccc2C#C)CCC1 Chemical compound CN1CCN(Cc(cc2)ccc2C#C)CCC1 OLOHEKLZHBXCOU-UHFFFAOYSA-N 0.000 description 1
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N CN1CCNCCC1 Chemical compound CN1CCNCCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 1
- CUAGQPWVAVIYHC-UHFFFAOYSA-N COC(c1c2[o]c(C3C=CC(CNC4COCC4)=CC3)cc2cc(F)c1)=O Chemical compound COC(c1c2[o]c(C3C=CC(CNC4COCC4)=CC3)cc2cc(F)c1)=O CUAGQPWVAVIYHC-UHFFFAOYSA-N 0.000 description 1
- SPCXJKWATXURQS-UHFFFAOYSA-N COC(c1cc(F)cc(I)c1O)=O Chemical compound COC(c1cc(F)cc(I)c1O)=O SPCXJKWATXURQS-UHFFFAOYSA-N 0.000 description 1
- DGHBWVVOJLVMFF-UHFFFAOYSA-N COC(c1cc(F)ccc1O)=O Chemical compound COC(c1cc(F)ccc1O)=O DGHBWVVOJLVMFF-UHFFFAOYSA-N 0.000 description 1
- OCTKXAKRWKBMBX-UHFFFAOYSA-N C[Si+](C)(C)C#Cc1ccc(C=O)cn1 Chemical compound C[Si+](C)(C)C#Cc1ccc(C=O)cn1 OCTKXAKRWKBMBX-UHFFFAOYSA-N 0.000 description 1
- FIMPLWHCENZJFA-DAFODLJHSA-N OC/C(/I)=C\CF Chemical compound OC/C(/I)=C\CF FIMPLWHCENZJFA-DAFODLJHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210028895.0A CN103242273B (zh) | 2012-02-09 | 2012-02-09 | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 |
| JP2014555927A JP5926821B2 (ja) | 2012-02-09 | 2013-01-14 | 2−アリールベンゾフラン−7−カルボキサミド系化合物、その製造方法および用途 |
| PCT/CN2013/070410 WO2013117120A1 (zh) | 2012-02-09 | 2013-01-14 | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 |
| BR112014019402-5A BR112014019402B1 (pt) | 2012-02-09 | 2013-01-14 | Composto 2-aril-benzofuran-7-carboxamida, ou sal farmacologicamente aceitável do mesmo e método para a preparação do composto |
| CA2863988A CA2863988C (en) | 2012-02-09 | 2013-01-14 | 2-aryl/heteroarylbenzofuran-7-formamide compounds, preparation method and use thereof |
| EP13746724.7A EP2813495B1 (en) | 2012-02-09 | 2013-01-14 | 2-arylbenzofuran-7-formamide compounds, preparation method and use thereof |
| US14/375,742 US9533965B2 (en) | 2012-02-09 | 2013-01-14 | 2-arylbenzofuran-7-formamide compounds, preparation method and use thereof |
| RU2014132159/04A RU2583900C2 (ru) | 2012-02-09 | 2013-01-14 | Соединения 2-арилбензофуран-7-формамида, способ их получения и применение |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210028895.0A CN103242273B (zh) | 2012-02-09 | 2012-02-09 | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103242273A CN103242273A (zh) | 2013-08-14 |
| CN103242273B true CN103242273B (zh) | 2015-06-03 |
Family
ID=48922178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210028895.0A Active CN103242273B (zh) | 2012-02-09 | 2012-02-09 | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9533965B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2813495B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5926821B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103242273B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014019402B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2863988C (cg-RX-API-DMAC7.html) |
| RU (1) | RU2583900C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013117120A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024187321A1 (zh) | 2023-03-10 | 2024-09-19 | 甫康(上海)健康科技有限责任公司 | 含有egfr抑制剂的药物组合物及其制备方法和应用 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102627620B (zh) * | 2012-04-10 | 2015-12-16 | 江苏先声药物研究有限公司 | 一类苯并呋喃衍生物及其医药应用 |
| MX2015006780A (es) | 2012-12-31 | 2015-08-06 | Cadila Healthcare Ltd | Derivados de ftalazin-1-(2h)-ona sustituida. |
| CN105272936B (zh) * | 2014-05-27 | 2019-05-17 | 中国科学院上海药物研究所 | 一类氮芳基苯并噻唑类parp抑制剂及其制备方法和用途 |
| CN109134409B (zh) | 2017-06-14 | 2023-09-29 | 中国科学院上海药物研究所 | 盐酸美呋哌瑞多晶型物及其制备方法与应用 |
| CN111320596B (zh) * | 2018-12-14 | 2024-07-05 | 甫康(上海)健康科技有限责任公司 | 盐酸美呋哌瑞多晶型物及其制备方法 |
| JP7805005B2 (ja) * | 2019-12-31 | 2026-01-23 | フーカン(シャンハイ) ヘルス テクノロジー カンパニー、 リミテッド | 腫瘍治療の医薬組み合わせとその使用 |
| US20240016775A1 (en) | 2020-02-24 | 2024-01-18 | Fukang (Shanghai) Health Technology Co., Ltd | Anti-coronavirus application of poly adp ribose polymerase inhibitor |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000029384A1 (de) * | 1998-11-17 | 2000-05-25 | Basf Aktiengesellschaft | 2-phenylbenzimidazole und 2-phenylindole, deren herstellung und anwendung |
| US7087637B2 (en) * | 2000-05-11 | 2006-08-08 | Basf Ag | Substituted indoles which are PARP inhibitors |
| CN101641014A (zh) * | 2006-12-28 | 2010-02-03 | 艾博特公司 | 聚(adp-核糖)聚合酶抑制剂 |
| WO2010054278A2 (en) * | 2008-11-10 | 2010-05-14 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL87451A0 (en) | 1987-09-04 | 1989-01-31 | Tanabe Seiyaku Co | Benzofuran derivatives,their preparation and pharmaceutical compositions containing them |
| JP2002515488A (ja) * | 1998-05-15 | 2002-05-28 | ギルフォード ファーマシューティカルズ インコーポレイテッド | カルボキサミド化合物、組成物、及びparp活性の抑制方法 |
| TR200101239T2 (tr) * | 1998-11-03 | 2001-11-21 | Basf Aktiengesellschaft | İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları |
| US7435837B2 (en) * | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| DE10351315A1 (de) | 2003-10-31 | 2005-06-16 | Aventis Pharma Deutschland Gmbh | 2-Phenyl-benzofuran-Derivate, Verfahren zur ihrer Herstellung und ihre Verwendung |
| CA2580833C (en) * | 2004-09-22 | 2010-12-21 | Pfizer, Inc. | Method of preparing poly(adp-ribose) polymerases inhibitors |
| JP5162465B2 (ja) * | 2005-11-15 | 2013-03-13 | アボット・ラボラトリーズ | 置換1h−ベンズイミダゾール−4−カルボキサミド類は強力なparp阻害薬である |
| MX2008014004A (es) * | 2006-05-02 | 2008-11-12 | Abbott Lab | 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes. |
| JP2010518146A (ja) | 2007-02-16 | 2010-05-27 | グラクソ グループ リミテッド | ベンゾフラン化合物 |
| US20090010884A1 (en) * | 2007-07-06 | 2009-01-08 | Wyeth | Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion |
| CN101998959B (zh) * | 2008-02-06 | 2013-08-28 | 生物马林药物股份有限公司 | 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂 |
| GB0806656D0 (en) | 2008-04-11 | 2008-05-14 | Karobio Ab | Novel estrogen receptor ligands |
| US8476309B2 (en) | 2009-08-20 | 2013-07-02 | The University Of Tennessee Research Foundation | Benzofuran cannabinoid compounds and related methods of use |
| GB0919380D0 (en) | 2009-11-04 | 2009-12-23 | Almac Discovery Ltd | Pharmaceutical compouds |
| CN102627620B (zh) * | 2012-04-10 | 2015-12-16 | 江苏先声药物研究有限公司 | 一类苯并呋喃衍生物及其医药应用 |
-
2012
- 2012-02-09 CN CN201210028895.0A patent/CN103242273B/zh active Active
-
2013
- 2013-01-14 BR BR112014019402-5A patent/BR112014019402B1/pt active IP Right Grant
- 2013-01-14 CA CA2863988A patent/CA2863988C/en active Active
- 2013-01-14 WO PCT/CN2013/070410 patent/WO2013117120A1/zh not_active Ceased
- 2013-01-14 RU RU2014132159/04A patent/RU2583900C2/ru active
- 2013-01-14 EP EP13746724.7A patent/EP2813495B1/en active Active
- 2013-01-14 JP JP2014555927A patent/JP5926821B2/ja active Active
- 2013-01-14 US US14/375,742 patent/US9533965B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000029384A1 (de) * | 1998-11-17 | 2000-05-25 | Basf Aktiengesellschaft | 2-phenylbenzimidazole und 2-phenylindole, deren herstellung und anwendung |
| US7087637B2 (en) * | 2000-05-11 | 2006-08-08 | Basf Ag | Substituted indoles which are PARP inhibitors |
| CN101641014A (zh) * | 2006-12-28 | 2010-02-03 | 艾博特公司 | 聚(adp-核糖)聚合酶抑制剂 |
| WO2010054278A2 (en) * | 2008-11-10 | 2010-05-14 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024187321A1 (zh) | 2023-03-10 | 2024-09-19 | 甫康(上海)健康科技有限责任公司 | 含有egfr抑制剂的药物组合物及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014132159A (ru) | 2016-03-27 |
| BR112014019402A8 (pt) | 2017-07-11 |
| US20150018542A1 (en) | 2015-01-15 |
| BR112014019402A2 (cg-RX-API-DMAC7.html) | 2017-06-20 |
| WO2013117120A1 (zh) | 2013-08-15 |
| RU2583900C2 (ru) | 2016-05-10 |
| BR112014019402B1 (pt) | 2020-12-15 |
| EP2813495A4 (en) | 2015-06-17 |
| JP5926821B2 (ja) | 2016-05-25 |
| JP2015511942A (ja) | 2015-04-23 |
| EP2813495B1 (en) | 2016-09-28 |
| CA2863988A1 (en) | 2013-08-15 |
| CA2863988C (en) | 2016-03-22 |
| US9533965B2 (en) | 2017-01-03 |
| CN103242273A (zh) | 2013-08-14 |
| EP2813495A1 (en) | 2014-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103242273A (zh) | 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途 | |
| CN105142634B (zh) | 包含Src同源-2结构域的致癌性蛋白酪氨酸磷酸酶-2(SHP2)的基于羟基吲哚羧酸的抑制剂 | |
| AU742641B2 (en) | Novel tricyclic compound | |
| CN101687798B (zh) | 制备用于调节激酶级联的组合物的过程及其使用方法 | |
| CN104169260A (zh) | 新三嗪衍生物 | |
| CN115768761B (zh) | 新颖苯并咪唑衍生物 | |
| EP3480199A1 (en) | Imidazopyridinamine phenyl derivative and use thereof | |
| TW200812970A (en) | Inhibitors of AKT (protein kinase B) | |
| CN102452988B (zh) | 一种喹唑啉衍生物及其制备方法 | |
| WO2022107745A1 (ja) | Covid-19の治療剤又は予防剤 | |
| CN108069954B (zh) | 含no供体的喹唑啉酮化合物 | |
| Wang et al. | Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of colorectal cancer | |
| CN109748914A (zh) | 吡啶并嘧啶类化合物及其应用 | |
| TW565559B (en) | Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament, and pharmaceutical preparations comprising them | |
| CN109096272A (zh) | 一种具有抗肿瘤活性的吲哚异羟肟酸类化合物及其应用 | |
| EP3684354B1 (en) | Xpa inhibitor compounds and their use | |
| CN102212032B (zh) | 一种5-羟基喹诺酮类衍生物及其制备方法和用途 | |
| WO2010062221A1 (ru) | Замещенные 2-(5-гидpokcи-2-metил-1н-иhдoл-3-ил)уkcуchыe кислоты и их эфиры и их применение для лечения вирусных заболеваний | |
| CN110903224A (zh) | 一种芳基磺酰胺类化合物、其制备方法、药物组合物及用途 | |
| CN111018686B (zh) | 6-苄亚基-2-芳基乙炔基环己烯酮衍生物及其制备方法和医药用途 | |
| CN115322120A (zh) | 一类小分子化合物及在制备治疗dhodh介导疾病药物中的用途 | |
| CN119528929B (zh) | 鬼臼毒素三氮唑醚衍生物及其制备方法和应用 | |
| CN115260081B (zh) | 一种磺酰胺类吲哚芳基砜衍生物及其制备方法与应用 | |
| WO2019234740A1 (en) | Mitogen-activated protein kinase kinase 7 inhibitors | |
| CN108129486A (zh) | 嘧啶酮衍生物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181102 Address after: 201203 555 Zhangjiang Road, Zhangjiang, Pudong New Area, Shanghai Co-patentee after: Fukang (Shanghai) Health Technology Co., Ltd. Patentee after: Shanghai Institute of Materia Medica, Chinese Academy of Sciences Address before: 201203 555 Zhangjiang Road, Zhangjiang, Pudong New Area, Shanghai Patentee before: Shanghai Institute of Materia Medica, Chinese Academy of Sciences |
|
| TR01 | Transfer of patent right |